Matching articles for "Kineret"
Issue 1688 · October 30, 2023
Drugs for Gout

Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint…

Med Lett Drugs Ther. 2023 Oct 30; 65(1688):169-75 doi:10.58347/tml.2023.1688a
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Issue 1688 · October 30, 2023
Comparison Table: Some Drugs for Gout (online only)

View the Comparison Table: Some Drugs for Gout

Med Lett Drugs Ther. 2023 Oct 30; 65(1688):e176-9 doi:10.58347/tml.2023.1688c
View the Comparison Table: Some Drugs for Gout
Issue 1637 · November 15, 2021
Drugs for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were…

Med Lett Drugs Ther. 2021 Nov 15; 63(1637):177-84
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Issue 1632 · September 6, 2021
Rilonacept (Arcalyst) for Recurrent Pericarditis

Rilonacept ( Arcalyst – Kiniksa), an interleukin-1 (IL-1) antagonist that has been available for years for treatment of cryopyrin-associated periodic syndromes, has now been approved by the FDA for treatment…

Med Lett Drugs Ther. 2021 Sep 6; 63(1632):143-4
Rilonacept ( Arcalyst – Kiniksa), an interleukin-1 (IL-1) antagonist that has been available for years for treatment of cryopyrin-associated periodic syndromes, has now been approved by the FDA for treatment of recurrent pericarditis and prevention of further recurrences in patients ≥12 years old. It is the first drug to be approved in the US for this indication. Anakinra (Kineret) , an IL-1 receptor antagonist FDA-approved for treatment of rheumatoid arthritis, has been used off-label for years for treatment of recurrent pericarditis.
Issue 1595 · April 6, 2020 Free
Table: Treatments Considered for COVID-19 (Archived) (online only)

View the Table: Treatments Considered for COVID-19

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):e1-289
View the Table: Treatments Considered for COVID-19
Issue 1567 · March 11, 2019
Drugs for Gout

Drugs for gout reduce the pain and inflammation of acute flares and lower serum urate levels in order to prevent recurrent flares, development of tophi, and joint damage.

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):33-7
Drugs for gout reduce the pain and inflammation of acute flares and lower serum urate levels in order to prevent recurrent flares, development of tophi, and joint damage.
Issue 1567 · March 11, 2019
Expanded Table: Some Drugs for Gout (online only)

View the Expanded Table: Some Drugs for Gout

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):e40-3
View the Expanded Table: Some Drugs for Gout
Issue 1552 · July 30, 2018
Drugs for Rheumatoid Arthritis

Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally do…

Med Lett Drugs Ther. 2018 Jul 30; 60(1552):123-8
Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally do not have an immediate analgesic effect, but over time they can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate ( Trexall , and others) is generally the drug of choice; it can be used for patients with low, moderate, or high disease activity. For mild disease, some clinicians prefer to start with hydroxychloroquine ( Plaquenil , and generics) and/or sulfasalazine ( Azulfidine , and others).
Issue 1552 · July 30, 2018
Expanded Table: Biologic Agents for Rheumatoid Arthritis (online only)

View Expanded Table: Biologic Agents for Rheumatoid Arthritis

Med Lett Drugs Ther. 2018 Jul 30; 60(1552):e130-4
View Expanded Table: Biologic Agents for Rheumatoid Arthritis
Issue 1527 · August 14, 2017
Sarilumab (Kevzara) for Rheumatoid Arthritis

The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second IL-6…

Med Lett Drugs Ther. 2017 Aug 14; 59(1527):134-6
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second IL-6 inhibitor to be approved for this indication; tocilizumab (Actemra) was approved earlier.
Issue 1458 · December 22, 2014
Drugs for Rheumatoid Arthritis

For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to…

Med Lett Drugs Ther. 2014 Dec 22; 56(1458):127-32
For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to control symptoms. Methotrexate is generally the DMARD of choice... DMARDs Disease-modifying antirheumatic drugs (DMARDs) are used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate ( Rheumatrex , and others) is generally the first DMARD prescribed; it can be used to treat mild, moderate, or severe RA. For mild disease, some clinicians prefer to start with hydroxychloroquine ( Plaquenil , and generics) and/or sulfasalazine ( Azulfidine , and others).
Issue 1438 · March 17, 2014
Drugs for Gout

The goals of gout treatment are threefold: treating acute inflammation, preventing flares, and lowering serum urate levels.

Med Lett Drugs Ther. 2014 Mar 17; 56(1438):22-4
The goals of gout treatment are threefold: treating acute inflammation, preventing flares, and lowering serum urate levels.
Issue 1423 · August 19, 2013
Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis

The FDA has approved the interleukin-1 (IL-1) beta inhibitor canakinumab ( Ilaris – Novartis) for treatment of systemic juvenile idiopathic arthritis (sJIA; formerly called juvenile rheumatoid arthritis or…

Med Lett Drugs Ther. 2013 Aug 19; 55(1423):65-6
The FDA has approved the interleukin-1 (IL-1) beta inhibitor canakinumab ( Ilaris – Novartis) for treatment of systemic juvenile idiopathic arthritis (sJIA; formerly called juvenile rheumatoid arthritis or Still’s disease) in children ≥2 years old. Canakinumab was approved earlier for treatment of cryopyrin-associated periodic syndromes (CAPS). Tocilizumab (Actemra) , an interleukin-6 (IL-6) inhibitor that has been available since 2010 for treatment of rheumatoid arthritis in adults, was also recently approved by the FDA for sJIA. Canakinumab is the only IL-1 inhibitor approved for this indication.
Issue 85 · September 1, 2009
Drugs for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is…

Treat Guidel Med Lett. 2009 Sep; 7(85):65-74
Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is induction or maintenance of remission. Table 1 on page 66 lists the drugs used to treat IBD with their formulations and cost. Table 2 on page 68 lists the drugs of choice and their doses for different indications. Table 3 on page 71 lists the drugs' adverse effects and recommendations for monitoring. More detailed guidelines are available from the American College of Gastroenterology.
Issue 81 · May 1, 2009
Drugs for Rheumatoid Arthritis

Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal…

Treat Guidel Med Lett. 2009 May; 7(81):37-46
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Issue 1229 · February 27, 2006
Abatacept (Orencia) for Rheumatoid Arthritis

Atacept ( Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to…

Med Lett Drugs Ther. 2006 Feb 27; 48(1229):17-8
Atacept ( Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Issue 40 · December 1, 2005
Drugs for Rheumatoid Arthritis

To prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, disease modifying anti-rheumatic drugs (DMARDs) are now used…

Treat Guidel Med Lett. 2005 Dec; 3(40):83-90
To prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, disease modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA). The DMARDs listed in the table on page 84 have no immediate analgesic effects, but can control symptoms and have been shown to delay and possibly stop progression of the disease. The NSAIDs listed in the table on page 88 have analgesic and anti-inflammatory effects, but may not affect the disease process. Oral corticosteroids can rapidly relieve joint symptoms and control systemic manifestations, but their chronic use is associated with many complications.
Issue 5 · January 1, 2003
Drugs for Rheumatoid Arthritis

Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs), listed in the table on page 26, have analgesic and anti-inflammatory effects, but may not affect…

Treat Guidel Med Lett. 2003 Jan; 1(5):25-32
Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs), listed in the table on page 26, have analgesic and anti-inflammatory effects, but may not affect the disease process. Corticosteroids can provide rapid relief of joint symptoms and control of systemic manifestations, but chronic use is associated with many complications. The "disease-modifying" anti-rheumatic drugs (DMARDs), listed on page 29, have no immediate analgesic effects, but can control symptoms and may delay progression of the disease (American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, Arthritis Rheum 2002; 46:328). Interactions of anti-rheumatic drugs with other drugs are listed in The Medical Letter Handbook of Adverse Drug Interactions, 2003.
Issue 1124 · February 18, 2002
Anakinra (Kineret) For Rheumatoid Arthritis

Anakinra (Kineret - Amgen), an interleuken-1 (IL-1) receptor antagonist, has been approved by the FDA for treatment of moderately to severly active rheumatoid arthritis in adults who have failed at least one…

Med Lett Drugs Ther. 2002 Feb 18; 44(1124):18-9
Anakinra (Kineret - Amgen), an interleuken-1 (IL-1) receptor antagonist, has been approved by the FDA for treatment of moderately to severly active rheumatoid arthritis in adults who have failed at least one disease-modifying anti-rheumatic drug(DMARD) such as methotrexate (Medical Letter 2000; 24:57).